Skip to main content
SpringerLink
Log in

Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

At present, three risk factors for the development of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients have been identified: the presence of antibodies against JC virus (JCV); the duration of natalizumab treatment, especially if longer than 2 years; and the use of immunosuppressants prior to receiving natalizumab. The most commonly used strategy to assess the individual PML risk includes serum anti-JCV antibody testing. Based on the knowledge on all known risk factors, an algorithm for PML risk stratification has been proposed, where patients with the highest PML risk are those with positive anti-JCV antibodies, treatment duration longer than 2 years, with or without prior history of immunosuppression. These patients would have an approximate incidence of PML of 11.1 (with prior immunosuppression) or 4.6 (without prior immunosuppression) cases per 1,000 patients treated with natalizumab (and treatment duration longer than 2 years). In this review, new data on PML risk factors and possible new strategies for PML risk stratification are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15–23.

    Article  CAS  PubMed  Google Scholar 

  2. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.

    Article  CAS  PubMed  Google Scholar 

  3. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–23.

    Article  CAS  PubMed  Google Scholar 

  4. Horga A, Castillo J, Rio J, et al. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol. 2011;52(6):321–30.

    CAS  PubMed  Google Scholar 

  5. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375–81.

    Article  CAS  PubMed  Google Scholar 

  6. Zurhein G, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science. 1965;148(3676):1477–9.

    Article  CAS  PubMed  Google Scholar 

  7. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143–52.

    Article  PubMed  Google Scholar 

  8. Biogen Idec® Official Site. http://www.biogenidec-international.com/tysabri_fact_sheet.aspx?ID=4698. Accessed Oct 2013.

  9. PubMed® Official Site. http://www.ncbi.nlm.nih.gov/pubmed. Accessed Oct 2013.

  10. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430–8.

    Article  PubMed Central  PubMed  Google Scholar 

  11. White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy—revisited. J Infect Dis. 2011;203(5):578–86.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72(5):779–87.

    Article  CAS  PubMed  Google Scholar 

  13. Iacobaeus E, Ryschkewitsch C, Gravell M, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler. 2009;15(1):28–35.

    Article  CAS  PubMed  Google Scholar 

  14. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol. 2003;9(Suppl 1):88–92.

    Article  CAS  PubMed  Google Scholar 

  15. Boster AL, Nicholas JA, Topalli I, et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 2013;70(3):398–402.

    Article  PubMed  Google Scholar 

  16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.

    Article  CAS  PubMed  Google Scholar 

  17. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–80.

    Article  CAS  PubMed  Google Scholar 

  18. Chesters PM, Heritage J, McCance DJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis. 1983;147(4):676–84.

    Article  CAS  PubMed  Google Scholar 

  19. Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009;199(6):837–46.

    Article  CAS  PubMed  Google Scholar 

  20. Zanotta N, Delbue S, Rossi T, et al. Molecular epidemiology of JCV genotypes in patients and healthy subjects from Northern Italy. J Med Virol. 2013;85(7):1286–92.

    Article  PubMed  Google Scholar 

  21. Havla J, Berthele A, Kumpfel T, et al. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab “infusion group”. Mult Scler. 2013;19(9):1213–5.

    Article  CAS  PubMed  Google Scholar 

  22. Reid CE, Li H, Sur G, et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis. 2011;204(2):237–44.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Bellizzi A, Anzivino E, Rodio DM, et al. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virol J. 2013;10(1):298.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Gorelik L, Reid C, Testa M, et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis. 2011;204(1):103–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Warnke C, Ramanujam R, Plavina T, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1199–205.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Perkins MR, Ryschkewitsch C, Liebner JC, et al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS pathog. 2012;8(11):e1003014.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Warnke C, Mausberg AK, Stettner M, et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology. 2013;81(16):1400–8.

    Article  CAS  PubMed  Google Scholar 

  28. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81(10):865–71.

    Article  CAS  PubMed  Google Scholar 

  29. Plavina T, Berman M, Njenga M, et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol. 2012;53(1):65–71.

    Article  CAS  PubMed  Google Scholar 

  30. Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70(5):742–50.

    Article  PubMed  Google Scholar 

  31. Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57(2):141–6.

    Article  CAS  PubMed  Google Scholar 

  32. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295–303.

    Article  PubMed  Google Scholar 

  33. Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ. JC virus antibody status underestimates infection rates. Ann Neurol. 2013;74(1):84–90.

    Article  PubMed  Google Scholar 

  34. Major EO, Frohman E, Douek D. JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med. 2013;368(23):2240–1.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Laroni A, Giacomazzi CG, Grimaldi L, et al. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol. 2012;7(3):665–72.

    Article  CAS  PubMed  Google Scholar 

  36. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5(3):e1000363.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Lin J, Bettin P, Lee JK, Ho JK, Sadiq SA. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab. J Neuroimmunol. 2013;261(1–2):123–8.

    Article  CAS  PubMed  Google Scholar 

  38. Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Ticho B. Use of JC virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosis [oral communication]. ENS Congress, Barcelona, June 2013.

Download references

Disclosures

Carmen Tur has received honoraria and support for travel from Merk-Serono, Serono Foundation, Sanofi-Aventis, Bayer-Schering, Teva Pharmaceuticals, and Novartis.

Xavier Montalban has received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals and Almirall.

The authors did not receive any specific funding for writing this article.

Author information

Authors and Affiliations

  1. Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain

    Carmen Tur & Xavier Montalban

Authors
  1. Carmen Tur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Montalban
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmen Tur.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tur, C., Montalban, X. Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis. CNS Drugs 28, 641–648 (2014). https://doi.org/10.1007/s40263-014-0168-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-014-0168-0

Keywords

Search

Navigation